A Phase 1/2 Study of Oral LOXO-292 in | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 1

5 participants needed

1 Location

Brief description of study

LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. This Phase 1/2 study of LOXO-292 is required to understand the PK, safety, and maximum tolerated dose (MTD) for LOXO-292 in patients and to permit the preliminary assessment of efficacy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 830166

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 1/2 Study of Oral LOXO-292 in Patients

Brief description of study

Eligibility of study

Find a site

Interested in the study